- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00672789
Adherence to Hydroxyurea in Children With Sickle Cell Anemia
Medication non-adherence is a true public health problem. Despite advancements in the molecular understanding of disease and improvements in therapy, patient health outcomes will not improve unless patients take prescribed medications regularly. Decreasing the gap between efficacious and effective therapy for patients with SCD is an essential research agenda. Hydroxyurea has been shown to be safe and efficacious in children and infants. However, the effectiveness of the prophylaxis depends on adherence to the recommended regimen. Medication adherence in SCD has previously been found to be sub-optimal in patients taking penicillin, desferoxamine, and pain medication. Adherence to HU has been studied to some extent in children with SCD. Based on estimates of adherence in other chronic illness we expect approximately 50% of patients to be >80% adherent with their HU administration. There is no gold standard for improving adherence to treatment. There have been a few attempts in the SCD population to improve adherence. These include a day camp to promote education about desferoxamine and peer support, a combination of a slide-show about SCD and it complications, weekly phone calls by the clinic social worker and a calendar, and a seven-phase educational program. Given the striking improvements in the peripheral blood smear findings of patients with SCD on HU therapy, with reduction in the numbers of sickled cells, we hypothesize that viewing the peripheral blood smear of patients with poor adherence to HU compared to a blood smear of someone on HU can be used to improve adherence in non-adherent patients.
We will conduct a randomized trial between the intervention of regularly showing children and their parents the peripheral blood smear and standard care, including reminders of the importance of compliance and review of complete blood count parameters, including WBC, MCV, and Hgb concentration. The outcome measures will be increase in hemoglobin concentration and %HbF and increase in perceived QOL. QOL will be measured with age-appropriate and parent/proxy PedsQL™. Medication adherence will also be monitored throughout the study with pharmacy prescription refills, physician assessment, and self-report via a visual analogue scale. Adherence estimates, hemoglobin concentration, %HbF and QOL will be measured at baseline, 3 months and 6 months.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Sickle cell anemia
- on Hydroxyurea for at least six months
- age 2-17.9 years
Exclusion Criteria:
- none
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 1
Blood Smear Education
|
education at baseline and three month follow-up
|
Aktiv komparator: 2
Standard education
|
standard education
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
treatment adherence
Tidsramme: six months
|
six months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Courtney D Thornburg, MD, MS, Duke University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00000118
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sigdcelleanemi
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennå
-
Bing HanFullførtPure Red Cell Aplasia, ervervetKina
-
Peking Union Medical College HospitalUkjent
-
Peking Union Medical College HospitalUkjentPure Red Cell Aplasia | Autoimmun hemolytisk anemi | Evans syndromKina
-
Institute of Hematology & Blood Diseases Hospital...AvsluttetErvervet Pure Red Cell AplasiaKina
-
Northwell HealthFullførtPure Red Cell Aplasia | Diamond Blackfan anemi | Blackfan Diamond syndrom | DBA | Medfødt hypoplastisk anemiForente stater
-
Adrianna Vlachos, MDAvsluttetPure Red Cell Aplasia | Diamond Blackfan anemiForente stater
-
National Heart, Lung, and Blood Institute (NHLBI)AvsluttetAplastisk anemi | Pure Red Cell Aplasia | Diamond Blackfan anemiForente stater
-
Johnson & Johnson Pharmaceutical Research & Development...FullførtRen rødcellet aplasiStorbritannia, Sverige, Sør-Afrika, Brasil, Canada, Tyskland, Norge, Thailand
Kliniske studier på Blood smear education
-
Morehouse School of MedicineGyneConcepts, Inc.Har ikke rekruttert ennå
-
Hospices Civils de LyonVaincre la MucoviscidoseFullførtCystisk fibroseFrankrike
-
University of WashingtonMinnesota Ovarian Cancer AllianceAvsluttetStadium III Eggstokkreft AJCC v8 | Stadium IIIA Eggstokkreft AJCC v8 | Stadium IIIA1 Eggstokkreft AJCC v8 | Stadium IIIA2 Eggstokkreft AJCC v8 | Stadium IIIB Eggstokkreft AJCC v8 | Stadium IIIC Eggstokkreft AJCC v8 | Stadium IV Eggstokkreft AJCC v8 | Stage IVA Eggstokkreft AJCC v8 | Stadium IVB Eggstokkreft... og andre forholdForente stater
-
M.D. Anderson Cancer CenterRekrutteringEndometrie klarcellet adenokarsinom | Endometrielt dedifferensiert karsinom | Endometrial serøst adenokarsinom | Ondartet uterin neoplasma | Endometrie mucinøst adenokarsinom | Uterin Corpus CarcinosarcomaForente stater
-
Thomas Jefferson UniversityRekrutteringProstata karsinomForente stater
-
Universidade Federal de Sao CarlosFullført
-
VA Office of Research and DevelopmentRekruttering
-
Tokat Gaziosmanpasa UniversityFullførtStigmatisering | Funksjonalitet | Kollegastøtte | Kroniske psykiske lidelser | Psykososial ferdighetstrening | InnsiktTyrkia
-
Lokman Hekim ÜniversitesiFullført